Advertisement Pharmaceutical Business review - Page 87 of 5294 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 15, 2026

Alentis and PinotBio partner to develop claudin-1 oncology ADCs

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.

The joint initiative aims to apply PinotBio’s platform technologies to Alentis’ antibody assets to address claudin-1. Credit: THICHA SATAPITANON/Shutterstock.com.